APOE in AD

U.S. researchers have shown that Eisai Co. Ltd.'s cancer drug Targretin bexarotene raises apolipoprotein E levels in the brain and partially reverses cognitive and behavioral deficits in a mouse model of Alzheimer's disease.¹ Based on the findings, the team founded ReXceptor Inc., which plans to begin a proof-of-concept AD trial in about two months.

Apolipoprotein E (APOE) occurs in three isoforms-APOE2, APOE3 and APOE4-that serve as lipid-carrying proteins in the serum and brain...